Coeptis Therapeutics Inc
NASDAQ:COEP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Malaysia Steel Works (KL) Bhd
KLSE:MASTEEL
|
MY |
|
L
|
Liquid Holdings Group Inc
OTC:LIQDQ
|
US |
Coeptis Therapeutics Inc
Inventory
Coeptis Therapeutics Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
Coeptis Therapeutics Inc
Glance View
Coeptis Therapeutics, Inc. is a pharmaceutical company focused on the development of therapeutics and technologies to disrupt conventional treatment paradigms. The company is headquartered in Wexford, Pennsylvania and currently employs 4 full-time employees. The company went IPO on 2002-07-29. The Company, through its subsidiary, Coeptis Pharmaceuticals, Inc., is engaged in developing cell therapy platforms for cancer. Its product portfolio comprises CD38-GEAR-NK and CD38-Diagnostic. The firm's CD38-GEAR-NK is an autologous, natural killer (NK) cell-based therapeutic that is derived from a patient’s own cells and gene-edited to enable combination therapy with anti-CD38 monoclonal antibodies (mAbs). Its CD38-Diagnostic is an in vitro screening tool that is intended to provide the ability to pre-determine, which cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies, either as monotherapy or in combination with CD38-GEAR-NK.
